Anmol Ganjoo of JM Financial says Lupin remains his top pick on perfect execution track records. He also says, sectoral tailwinds will help Sun Pharma, though Ranbaxy benefits are over-rated and medicines super-priced.
first published: Aug 20, 2015 03:37 pm
A collection of the most-viewed Moneycontrol videos.

New Year Party Or Year-End Blues? Bulls In Focus| Top Stock Bets & 2026 Outlook| Opening Bell Live

Nifty Trades in a Narrow 100-Point Range on 2025’s Final F&O Expiry | Closing Bell Live

Small-Caps & Risk: What Investors Often Miss

Nifty’s Best Case Target & Top Stock Bets For 2026| IPO Wave Set To Get Bigger| Opening Bell Live
You are already a Moneycontrol Pro user.

